Samuel Rosner, MD, and Laura Alder, MD, discuss factors that help inform frontline treatment selection in EGFR-mutated NSCLC.
Back
Optimizing Contemporary Management of EGFR-Mutated Non–Small Cell Lung Cancer
Samuel Rosner, MD, and Laura Alder, MD, discuss optimal approaches to the current management of EGFR-mutated non–small cell lung cancer.
Optimizing Contemporary Management of EGFR-Mutated Non–Small Cell Lung Cancer
Episodes
All
All
Samuel Rosner, MD, and Laura Alder, MD, discuss combination vs monotherapy approaches in EGFR-mutated NSCLC.
Samuel Rosner, MD, and Laura Alder, MD, discuss how MET status and other factors can help inform sequencing decisions in EGFR-mutated NSCLC.
Samuel Rosner, MD, and Laura Alder, MD, discuss treatment approaches following frontline use of the MARIPOSA or FLAURA-2 regimens in EGFR-mutated NSCLC.
Samuel Rosner, MD, and Laura Alder, MD, discuss how antibody-drug conjugates have affected the EGFR-mutated NSCLC treatment paradigm.
Samuel Rosner, MD, and Laura Alder, MD, discuss AE management and compliance strategies for patients with EGFR-mutated NSCLC.
Samuel Rosner, MD, and Laura Alder, MD, discuss ongoing research to watch in EGFR-mutated NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
2
ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC
3
Mo-Rez Advances Into Combination Studies Following Robust Responses in Gynecologic Cancers
4
mRNA Vaccines May Help Increase Long-Term Disease Control in PDAC
5